Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: No Medication Clear all
Completed Phase 3 Interventional Results available

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

NCT02496884
View directory record Official record
Conditions
Fibromyalgia
Interventions
DS-5565, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Phoenix, Arizona • Colton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

NCT03570892
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Recruiting Phase 1 Interventional

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

NCT05372614
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Neratinib Maleate, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Lancaster, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

NCT00770887
View directory record Official record
Conditions
Fertility
Interventions
Self administration
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Phase 1 Interventional

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

NCT02048709
View directory record Official record
Conditions
Solid Tumor
Interventions
GDC-0919
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Phase 3 Interventional

Acupuncture for Post-Thoracotomy Pain

NCT00142532
View directory record Official record
Conditions
Lung Cancer, Pain
Interventions
Acupuncture and Questionnaires, Placebo Acupuncture, Questionnaires
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2009 · Synced Sep 17, 2026, 2:00 AM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

NCT05884554
View directory record Official record
Conditions
COVID-19
Interventions
PF-07817883
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Anaheim, California • Garden Grove, California • Montclair, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Improving Adherence to Web-Based Cessation Programs: A Social Network Approach

NCT01544153
View directory record Official record
Conditions
Smoking Cessation
Interventions
WEB, Social Network, Nicotine Replacement Therapy (NRT)
Behavioral
Lead sponsor
Truth Initiative
Other
Eligibility
18 Years and older
Enrollment
5,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Not applicable Interventional

Using Reinforcement Learning to Personalize Electronic Health Record Tools to Facilitate Deprescribing

NCT06660979
View directory record Official record
Conditions
Aging
Interventions
Reinforcement learning
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breathwork Training Reduces Anxiety In Outpatient Gastrointestinal Procedures

NCT07647341
View directory record Official record
Conditions
Anxiety
Interventions
paced breathwork
Behavioral
Lead sponsor
Calm and Sense Technologies LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Jupiter, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

NCT02118922
View directory record Official record
Conditions
Keratoconus, Ectasia, Crosslinking, Fuchs' Endothelial Dystrophy
Interventions
Brillouin imaging
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 17, 2026, 2:00 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Angiotensin II in Liver Transplantation

NCT04901169
View directory record Official record
Conditions
Liver Transplant; Complications, Vasoplegia
Interventions
Angiotensin II, Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

NCT04108156
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
88
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight

NCT01828554
View directory record Official record
Conditions
Obesity, Neoplasms
Interventions
Xeloda
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 17, 2026, 2:00 AM EDT
Completed No phase listed Observational

Metabolomics of Obstructive Sleep Apnea

NCT04572269
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
No Intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 75 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01711359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
47
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Cognition and Psychiatric Disorder Symptoms During Cannabis Abstinence Using a Novel Discordant Twin Design

NCT05160688
View directory record Official record
Conditions
Cannabis
Interventions
Contingency management
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Years to 47 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Recruiting Phase 4 Interventional

Magnesium and Cramping

NCT06745388
View directory record Official record
Conditions
Uterine Cramps, Postoperative Pain Management, Hysteroscopy
Interventions
Magnesium sulfate, Ketamine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 17, 2026, 2:00 AM EDT
Recruiting Phase 1 Interventional

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

NCT04248569
View directory record Official record
Conditions
Fibrolamellar Hepatocellular Carcinoma (FLC)
Interventions
DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 17, 2026, 2:00 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Analgesic Techniques for Rib Fractures

NCT06519929
View directory record Official record
Conditions
Rib Fractures
Interventions
ESP block with catheter using ropivacaine (bolus followed by continuous infusion), Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h
Procedure · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 17, 2026, 2:00 AM EDT
Active, not recruiting Phase 2 Interventional

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

NCT07157254
View directory record Official record
Conditions
Angelman Syndrome
Interventions
No intervention, GTX-102
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
1 Year to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

NCT03858894
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
13
States / cities
Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 17, 2026, 2:00 AM EDT